Therapeutics case studies

Learn more on how we bring life changing therapies to market.

Providing empirically based guidance and built-to-spec models and solutions across every phase of clinical research and lifecycle management for therapeutic development.

High-performing sites during COVID-19 in Women’s Health

A biotechnology company, dedicated to transforming Women’s Health, was running a phase 3 study in the treatment of moderate-to-severe vasomotor symptoms in postmenopausal women with a global enrollment target of 1,200 patients.

Beating patient recruitment target with enhanced patient experience

Accellacare was awarded an osteoarthritis study by a large biotech organisation. The study required recruitment of 1200+ patients across 20+ sites and four countries.

Overcoming the challenges of COVID-19 clinical trial conditions

A large biotech company contracted Accellacare to drive recruitment in a clinical trial to test the safety and
efficacy of a treatment for ambulatory patients with COVID-19. The Accellacare site in Wilmington, NC was selected for the study in August of 2020.

High performing sites in cardiovascular study

Four studies were awarded by a pharma organisation over a period of less than two years, with overlapping
start-up through close out timelines. Milestone expectations were aggressive, requiring an innovative approach and rapid start-up.

Exceeding expectations in a c. diff vaccine study

Five Accellacare sites were selected to participate in a clostridium difficile (c. diff) vaccine study being conducted
by a large pharma sponsor and ICON.

Digital solutions to reduce risk potential for six-study dermatology programme

A large pharma company conducted an extensive atopic dermatitis program consisting of six studies with complex protocols and up to 537 active sites per study. The sponsor contacted ICON to implement a centralised digital solution to better manage this massive study and reduce risk potential.

Digital solutions for an evolving COVID-19 environment

One of the top five pharmaceutical companies in the world selected ICON to initiate, manage and operate a phase 1/2/3 randomised, placebo-controlled vaccine clinical trial for SARS-CoV-2, the virus that causes COVID-19.

Optimising biosimilar development

ICON’s proactivity in risk mitigation, commitment to the study, project planning and communication contributed significantly to the ultimate success of the study.

Patient support services

A sponsor needed to recruit nearly 500 patients for a pivotal study in an ultra rare disease. The study's demanding protocol posed significant difficulties for patients. ICON was able to revise the protocol, reducing patient burden, and implemented a global recruitment strategy and additional support that allowed recruitment to be completed ahead of schedule, saving the sponsor an estimated $700,000.